Free Trial Information
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...compounds are the PDE-4 inhibitor Otezla, Takeda’s Takhzyro lanadelumab...
Read More
BioCentury | Dec 10, 2020
Product Development

Vaccines aren’t enough: COVID R&D’s adaptive platform trial aims to fill the need for new therapies

...members —Otezla apremilast from Amgen, Takhzyro lanadelumab...
Read More
BioCentury | May 21, 2019
Clinical News

BioCryst makes case for oral HAE therapy even as Phase III data disappoint investors

...access to at least three marketed subcutaneous or IV HAE prophylactics in the U.S.: Takhzyro lanadelumab-flyo...
Read More
BioCentury | Jan 25, 2019
Finance

Venrock spreads HAE bets

...is now part of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Dyax's HAE program became Takhzyro lanadelumab...
Read More
BioCentury | Jan 12, 2019
Finance

We all fall down

...to treat ALK-positive advanced NSCLC Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) (A) EC approves Takhzyro lanadelumab...
Read More
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
Read More
BioCentury | Oct 26, 2018
Clinical News

CHMP backs Takhzyro, Dengue vaccine, biosimilar Herceptin

...EMA’s CHMP on Oct. 19 recommended several approvals, including hereditary angioedema (HAE) mAb Takhzyro lanadelumab, dengue...
...Paris, France Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Biocon Ltd. (NSE:BIOCON; BSE:532523), Bangalore, India Product: Takhzyro lanadelumab-flyo...
...MYL-1401O (Compound #), biosimilar trastuzumab (Generic), Ogivri (Other), Hertraz (Other), CANMab (Other) Takhzyro (lanadelumab, lanadelumab-flyo, SHP643, dx-2930) Tetravalent...
Read More
BioCentury | Oct 19, 2018
Company News

CHMP backs Takhzyro, Dengue vaccine, biosimilar Herceptin

...EMA’s CHMP recommended several approvals Friday, including hereditary angioedema (HAE) mAb Takhzyro lanadelumab, dengue vaccine Dengvaxia...
...MYL-1401O (Compound #), biosimilar trastuzumab (Generic), Ogivri (Other), Hertraz (Other), CANMab (Other) Takhzyro (lanadelumab, lanadelumab-flyo, SHP643, dx-2930) Tetravalent...
Read More
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...to undergo a medical or dental procedure Shire plc (LSE:SHP; NASDAQ:SHPG) (A) FDA approves Takhzyro lanadelumab-flyo...
Read More
BioCentury | Sep 21, 2018
Clinical News

FDA wants extra trial for Pharming's Ruconest as HAE Prophylactic

...Patients have access to at least three marketed HAE prophylactics in the U.S., including Takhzyro lanadelumab-flyo...
Read More
Items per page:
1 - 10 of 54